Importantly, another trial evaluating the effect of a virus based on the Delta-24 platform expressing the OX40 ligand for recurrent adult gliomas (DNX-2440; NTC03714334) is currently ongoing at our institution, and 11 patients have thus far been enrolled, with no relevant toxicities. This evidence concerns the gene TNFRSF4 and glioma.